Bacterial Carriers for Glioblastoma Therapy.

Published

Journal Article

Treatment of aggressive glioblastoma brain tumors is challenging, largely due to diffusion barriers preventing efficient drug dosing to tumors. To overcome these barriers, bacterial carriers that are actively motile and programmed to migrate and localize to tumor zones were designed. These carriers can induce apoptosis via hypoxia-controlled expression of a tumor suppressor protein p53 and a pro-apoptotic drug, Azurin. In a xenograft model of human glioblastoma in rats, bacterial carrier therapy conferred a significant survival benefit with 19% overall long-term survival of >100 days in treated animals relative to a median survival of 26 days in control untreated animals. Histological and proteomic analyses were performed to elucidate the safety and efficacy of these carriers, showing an absence of systemic toxicity and a restored neural environment in treated responders. In the treated non-responders, proteomic analysis revealed competing mechanisms of pro-apoptotic and drug-resistant activity. This bacterial carrier opens a versatile avenue to overcome diffusion barriers in glioblastoma by virtue of its active motility in extracellular space and can lead to tailored therapies via tumor-specific expression of tumoricidal proteins.

Full Text

Duke Authors

Cited Authors

  • Mehta, N; Lyon, JG; Patil, K; Mokarram, N; Kim, C; Bellamkonda, RV

Published Date

  • March 2017

Published In

Volume / Issue

  • 4 /

Start / End Page

  • 1 - 17

PubMed ID

  • 28345020

Pubmed Central ID

  • 28345020

Electronic International Standard Serial Number (EISSN)

  • 2372-7705

International Standard Serial Number (ISSN)

  • 2372-7705

Digital Object Identifier (DOI)

  • 10.1016/j.omto.2016.12.003

Language

  • eng